Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON: tezepelumab in children aged 5 to <12 years with uncontrolled severe asthma
CTR20240982Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tezepelumab in severe asthma, asthma, sponsored by AstraZeneca. Started May 2024; status: active.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on CTR20240982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240982.